title: [Update on first-line and relapse chemotherapy for testicular cancer].
abstract: Germ-cell cancer (GCC) is still the most common cancer diagnosis in men between the ages of 20 and 45 years with an increasing incidence. Due to effective and standardized algorithms that have been developed to stratify patients into different risk groups, remarkable progress has been made in the medical treatment of testicular cancer with an overall cure rate of 88%. The application of surgery, radiotherapy and chemotherapy, the choice of chemotherapy agents as well as treatment duration is defined in international consensus guidelines. The guidelines are based on histology, tumor stages and presence or absence of already known and well-established risk factors. These stringent parameters guarantee the optimal curative treatment options for each GCC patient and can avoid overtreatment as well as undertreatment. For patients with early stage disease, careful consideration between possible side effects due to an adjuvant therapy and the expected relapse rate must be made, whereas in advanced tumor stages the optimal sequence of chemotherapy, surgery and radiotherapy is the focus. In patients who progress or relapse after first-line therapy, the issue of optimal treatment represents a particular challenge and is far more complex. It needs to take into account the analysis of special prognostic variables for a further risk-tailored therapy. A careful weighting between the chosen regimen and the often higher rate of treatment failure in contrast to increased toxic side-effects is mandatory.The disregard of accurate risk stratification and application of accepted treatment standards for patients with GCC at the time of initial diagnosis or at relapse is associated with developing more extensive disease and more intensive treatment. It also results in lower cure rates with the need for further therapy or leads to death of the patient without ever having had a chance for cure.
authors.affiliation: Bereich Konservative Urologische Onkologie, Klinik für Urologie, Universitätsklinikum Düsseldorf, Moorenstraße 5, 40255, Düsseldorf, Deutschland, anja.lorch@med.uni-duesseldorf.de.
authors.forename: A
authors.initials: A
authors.lastname: Lorch
authors.forename: P
authors.initials: P
authors.lastname: Albers
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects* / Q000379:methods*; D008297:Male; D013736:Testicular Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents